[HTML] mdpi.com

[HTML][HTML] The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson's Disease

M Hoon, JP Petzer, F Viljoen, A Petzer - Molecules, 2017 - mdpi.com
l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic
relief of the advanced stages of Parkinson's disease. The oral bioavailability of l-dopa …
被引用次数：13 相关文章

The design and evaluation of an l-dopa-lazabemide prodrug for the treatment of Parkinson's disease

M Hoon, JP Petzer, F Viljoen, A Petzer - 2017 - repository.nwu.ac.za
l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic
relief of the advanced stages of Parkinson's disease. The oral bioavailability of l-dopa …

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson's Disease

M Hoon, J Petzer, F Viljoen, A Petzer - agris.fao.org
l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic
relief of the advanced stages of Parkinson's disease. The oral bioavailability of l-dopa …

The Design and Evaluation of an L-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.

M Hoon, JP Petzer, F Viljoen, A Petzer - Molecules, 2017 - search.ebscohost.com
L-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic
relief of the advanced stages of Parkinson's disease. The oral bioavailability of L-dopa …
[HTML] nih.gov

[HTML][HTML] The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson's Disease

M Hoon, JP Petzer, F Viljoen… - Molecules: A Journal of …, 2017 - ncbi.nlm.nih.gov
Abstract l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the
symptomatic relief of the advanced stages of Parkinson's disease. The oral bioavailability of l …

The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease

M Hoon, JP Petzer, F Viljoen… - Molecules (Basel …, 2017 - pubmed.ncbi.nlm.nih.gov
l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic
relief of the advanced stages of Parkinson's disease. The oral bioavailability of l-dopa …

The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.

M Hoon, JP Petzer, F Viljoen, A Petzer - Molecules (Basel …, 2017 - europepmc.org
Abstract l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the
symptomatic relief of the advanced stages of Parkinson's disease. The oral bioavailability of l …
[PDF] academia.edu

[PDF][PDF] The Design and Evaluation of an L-Dopa–Lazabemide Prodrug for the Treatment of Parkinson's Disease

M Hoon, JP Petzer, F Viljoen, A Petzer - Molecules, 2017 - academia.edu
L-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic
relief of the advanced stages of Parkinson's disease. The oral bioavailability of L-dopa …
[PDF] semanticscholar.org

[PDF][PDF] The Design and Evaluation of an L-Dopa–Lazabemide Prodrug for the Treatment of Parkinson's Disease

M Hoon, JP Petzer, F Viljoen, A Petzer - Molecules, 2017 - pdfs.semanticscholar.org
L-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic
relief of the advanced stages of Parkinson's disease. The oral bioavailability of L-dopa …
[PDF] archive.org

[PDF][PDF] The Design and Evaluation of an L-Dopa–Lazabemide Prodrug for the Treatment of Parkinson's Disease

M Hoon, JP Petzer, F Viljoen, A Petzer - Molecules, 2017 - scholar.archive.org
L-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic
relief of the advanced stages of Parkinson's disease. The oral bioavailability of L-dopa …